This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: F23.1 (Acute polymorphic psychotic disorder with symptoms of schizophrenia) | Special Copayment Reduction: V161 (severe intractable disease, 5 years) |
| B. Synonyms | Cycloid psychosis with symptoms of schizophrenia, bouffée délirante with symptoms of schizophrenia |
| C. Adult onset | Possibility of first presenting in adulthood Very high — onset is concentrated in early adulthood (18 to 30s), and clinical distinction from the first episode of schizophrenia is important; the F23.1 diagnosis is maintained if symptoms resolve within 1 month. |
| 1. History | Same historical origin as F23.0 (bouffée délirante); distinguished from F23.0 by the accompaniment of schizophrenia-specific symptoms; set in ICD-10 as an intermediate category considering continuity with the schizophrenia spectrum. |
| 2. Causes | Genetic vulnerability to the schizophrenia spectrum presumed to be greater than in F23.0; includes cases in which acute stress triggers the first episode in individuals with a genetic predisposition to schizophrenia. |
| 3. Genetics | Schizophrenia-related genetic burden presumed to be higher than in F23.0; some patients later transition to a diagnosis of schizophrenia; family history of schizophrenia is a predictor of transition. |
| 4. General epidemiology | Part of the F23 group; incidence presumed to be lower than F23.0; rate of transition to schizophrenia higher than F23.0 (about 20-30%); tends to be somewhat higher in young men in early adulthood. |
| 5. Pathophysiology | In addition to the F23.0 mechanism, a schizophrenia predisposition (prefrontal-limbic abnormalities, dopamine dysregulation) underlies it; acute stress triggers the first psychotic episode in individuals with latent schizophrenia vulnerability. |
| 6. Symptoms | Polymorphic symptoms of F23.0 + accompanying schizophrenia-specific symptoms (Schneider first-rank symptoms: thought broadcasting, thought insertion, passivity experiences, etc.); the polymorphism with rapidly changing symptoms is retained. |
| 7. Signs | Acute signs similar to F23.0 with added schizophrenia-specific symptoms; thought disorder (loosening of associations, thought blocking), passivity experiences, first-rank auditory hallucinations, etc. may be observed. |
| 8. Screening | Same immediate evaluation approach as F23.0; structured interview to confirm schizophrenia first-rank symptoms is important; exclusion of organic causes essential. |
| 9. Diagnosis | ICD-10 F23.1: F23.0 criteria met + accompanying Schneider first-rank symptoms or schizophrenia-specific symptoms; F23.1 maintained if lasting less than 1 month, reclassified as schizophrenia (F20) if persisting longer. |
| 10. Treatment | More active antipsychotic treatment than F23.0; longer maintenance treatment period (6-12 months or more) considering the risk of transition to schizophrenia; enhanced monitoring of course. |
| 11. Prognosis | Prognosis somewhat poorer than F23.0; about 20-30% transition to schizophrenia; long-term follow-up essential because of the risk of relapse and transition even after complete remission. |
| 12. Prevention | In addition to the same stress management and relapse prevention principles as F23.0, strengthened maintenance drug treatment considering the risk of transition to schizophrenia; education for early detection of signs of transition to schizophrenia. |
| 13. References | Pillmann F, Marneros A. Longitudinal follow-up in acute and transient psychotic disorders and schizophrenia. British Journal of Psychiatry. 2005 … and 9 other papers |
Acute polymorphic psychotic disorder with symptoms of schizophrenia (F23.1) shares the same historical origin as F23.0, but because schizophrenia-specific symptoms appear together, it is a clinical category occupying an intermediate position on the spectrum between schizophrenia and acute reactive psychosis. The concept of bouffée délirante in 19th-century French psychiatry originally described acute polymorphic psychosis as a whole, without distinction according to the presence of schizophrenia-specific symptoms. Later, during the development of ICD-10, F23.0 (without) and F23.1 (with) were distinguished on the basis of the presence of schizophrenia-specific symptoms (Schneider first-rank symptoms).
The clinical significance of this distinction is twofold. First, F23.1 has a higher risk of transition to schizophrenia than F23.0 and requires closer follow-up of the course. Second, the accompaniment of Schneider first-rank symptoms functions as a warning sign (red flag) for later confirmation of schizophrenia. The Halle Study, led by the German psychiatrists Pillmann and Marneros, provided the most important data on long-term follow-up of the F23 group, and it demonstrated that F23.1 forms a prognostic group independent of F23.0.
The DSM system has no category directly corresponding to F23.1. Brief psychotic disorder (F23) in DSM-5 does not distinguish the presence of schizophrenia-specific symptoms and is based on a duration of less than 1 month. In ICD-11 the concept of F23.1 was retained while the diagnostic criteria were partially refined. In Korea, ICD-10 coding is the standard, so F23.1 is used in clinical and administrative coding.
The cause of F23.1 shares the multifactorial model of F23.0, but because of the characteristic accompaniment of schizophrenia-specific symptoms, genetic vulnerability to the schizophrenia spectrum is presumed to be more involved. Some of these patients may in fact be experiencing the first episode of schizophrenia.
Vulnerability to the schizophrenia spectrum: the accompaniment of Schneider first-rank symptoms is likely an expression of genetic vulnerability to the schizophrenia spectrum. The frequency of pathogenic variants in schizophrenia-related genes (DISC1, NRG1, DTNBP1, COMT, etc.) in these patients is presumed to be higher than in F23.0 patients, but studies directly comparing them are still lacking. Clinical data showing a higher risk of transition to schizophrenia after an F23.1 episode when there is a family history of schizophrenia support this.
Role of acute stress: as in F23.0, acute psychosocial stress plays a role in triggering the first psychotic episode in vulnerable individuals. In F23.1, the difference is that this vulnerability more often includes a schizophrenia predisposition than in F23.0. HPA axis hyperactivity, a dopamine surge, and sleep deprivation trigger an acute psychotic episode including first-rank symptoms in individuals carrying schizophrenia-predisposing genes.
Association with postpartum psychosis: part of postpartum psychosis meets the criteria for F23.1, and in particular the abrupt postpartum hormonal changes and sleep deprivation sometimes trigger an acute episode including schizophrenia first-rank symptoms in women with a schizophrenia predisposition. In the subsequent course, some differentiate into schizophrenia, some into bipolar disorder, and some into full recovery.
Dopamine dysregulation: in individuals with a schizophrenia predisposition, the threshold for mesolimbic dopamine hyperactivity is low, so acute psychosis including schizophrenia first-rank symptoms can be triggered even by relatively mild stress. This lowered threshold is the neurobiological basis that explains the continuity of F23.1 with the schizophrenia spectrum.
The genetics of F23.1 is understood as intermediate between F23.0 and schizophrenia, with a schizophrenia-related genetic burden presumed to be greater than F23.0 and smaller than chronic schizophrenia.
Family study data: there is a clinical observation that the incidence of schizophrenia in first-degree relatives of F23.1 patients is higher than in the general population. In F23.0 the risk of mood disorders is higher in relatives, whereas in F23.1 the risk of schizophrenia tends to be reported as relatively higher. This suggests that F23.0 and F23.1 may be separate clinical groups sharing different genetic bases.
Transition to schizophrenia and heredity: in long-term follow-up studies, about 20-30% of F23.1 patients later transition to a diagnosis of schizophrenia. Predictors of transition include persistence of schizophrenia first-rank symptoms, family history of schizophrenia, and decline in premorbid social function. This transition risk suggests that part of F23.1 is the initial episode of schizophrenia and can be viewed as a clinical expression of genetic overlap.
Relevance of polygenic risk score: there are study results showing that the higher the schizophrenia polygenic risk score (PRS), the higher the risk of transition to schizophrenia after an acute psychotic episode. In F23.1 patients, schizophrenia PRS evaluation may help predict long-term prognosis, but evidence is still insufficient to use it as a clinical standard.
Clinical significance: when diagnosing F23.1, it is recommended to systematically confirm the family history of schizophrenia, and when there is a family history, to explain the risk of transition to schizophrenia clearly to the patient and family and to plan longer maintenance treatment and intensive follow-up.
F23.1 is a subcategory of the F23 group, estimated to have a lower incidence than F23.0 and a higher rate of transition to schizophrenia.
Incidence estimate: the proportion accounted for by F23.1 within the annual incidence of the F23 group as a whole (about 6-9 per 100,000 population) varies by study. In European cohort studies including the Halle Study, F23.1 tends to occur at a lower proportion than F23.0. Because diagnostic accuracy depends on careful evaluation of the presence of accompanying symptoms, the actual proportion varies with the research institution and methodology.
Sex and age: F23.1 tends to show a sex and age distribution similar to schizophrenia. That is, it partially overlaps with the onset pattern of schizophrenia, with somewhat earlier onset in men (early 20s) and slightly later onset in women (late 20s to 30s). This suggests that F23.1 includes a group closer to the schizophrenia spectrum.
Regional differences: as with the F23 group as a whole, higher incidence may be reported in developing countries, but F23.1-specific data are limited. In immigrant groups in Western countries, the first episode of schizophrenia is not infrequently first diagnosed as F23.1.
Rate of transition to schizophrenia: the most important epidemiological characteristic of F23.1 is that its rate of transition to schizophrenia is significantly higher than F23.0 (about 10-15%). In long-term follow-up studies, about 20-30% of F23.1 patients are rediagnosed with schizophrenia within several years. This supports the need for more intensive long-term follow-up of F23.1 patients in clinical practice.
The pathophysiology of F23.1 is understood by a model in which, in addition to the acute stress-dopamine hyperactivity mechanism shared with F23.0, a prefrontal-limbic regulatory abnormality due to schizophrenia predisposition underlies it, giving rise to schizophrenia-specific symptoms such as Schneider first-rank symptoms.
Schizophrenia predisposition and dopamine dysregulation: in individuals with a schizophrenia predisposition (carrying related gene variants, underlying neurodevelopmental abnormality), decreased prefrontal dopamine D1 receptor activity and mesolimbic dopamine D2 receptor hypersensitivity are present to some extent even at baseline. The surge in cortisol due to acute stress sharply aggravates this baseline abnormality, producing first-rank symptoms. In this mechanism, the presence of a schizophrenia predisposition is the neurobiological basis distinguishing F23.1 from F23.0.
Neurobiology of Schneider first-rank symptoms: first-rank symptoms such as thought broadcasting, thought insertion, and thought withdrawal are explained as a disturbance of the self-other boundary. Neurologically, there is a theory that abnormal fronto-temporal connectivity causes internally self-generated thoughts to be mistaken as coming from outside. In a state of acute dopamine hyperactivity, this connectivity abnormality may transiently worsen and first-rank symptoms appear, and then symptoms may resolve as dopamine normalizes.
Neuroplasticity and recovery: the reason rapid recovery is possible even in F23.1 is that the fixed structural brain abnormalities seen in schizophrenia (gray matter reduction, decreased synaptic density) have often not yet formed. However, because the baseline vulnerability is greater than in F23.0, there is a risk that structural changes accumulate after repeated episodes, and this may become a pathway of transition to schizophrenia.
The symptoms of F23.1 take the form of the polymorphic acute psychotic symptoms of F23.0 with added schizophrenia-specific symptoms (Schneider first-rank symptoms or criterion A symptoms of the schizophrenia diagnostic criteria).
Polymorphic symptoms: as in F23.0, abrupt onset within 2 weeks and rapidly changing hallucinations, delusions, confusion, and mood changes appear. The polymorphism, in which symptoms change dramatically within hours or days, is retained.
Schizophrenia-specific symptoms: Schneider first-rank symptoms accompany. These include thought broadcasting (the experience that one's thoughts are spread to others), thought insertion (the experience that thoughts are inserted into one's head from outside), thought withdrawal (the experience that thoughts are taken away by an external agent), passivity experiences (the experience that bodily actions, feelings, and will are controlled by an external force), third-person auditory hallucinations (two or more voices talking about oneself), and auditory hallucinations commenting on one's actions. These first-rank symptoms appear in a polymorphic context, and being transient and rapidly changing is a characteristic of F23.1.
Absence of negative symptoms: unlike schizophrenia, prominent negative symptoms (avolition, alogia, apathy) are absent or extremely mild. Premorbid social functioning is relatively preserved, and there is no baseline decline in cognitive function. This is an important clinical characteristic distinguishing F23.1 from schizophrenia.
Duration: the F23.1 diagnosis is maintained if symptoms last less than 1 month. It is an acute episode that does not meet the 1-month criterion required for the diagnosis of schizophrenia. If it lasts 1 month or longer, reclassification as schizophrenia (F20) or schizoaffective disorder (F25) is considered.
The clinical signs of F23.1 consist of the acute signs of F23.0 plus the physical findings of schizophrenia-specific symptoms.
Mental status examination in the acute phase: as in F23.0, severe agitation, confusion, and abrupt mood changes appear. In addition, passivity experiences (sense of external control), thought broadcasting/insertion/withdrawal, and third-person auditory hallucinations are observed in thought content. Abnormalities of thought content in speech (statements that one's thoughts belong to others, thoughts inserted from outside, etc.) are reported. Affect is extremely unstable and confused, and thought blocking may appear.
Clinical distinction from F23.0: statements during the interview such as 'my thoughts can be heard on television (thought broadcasting),' 'someone puts thoughts into my head (thought insertion),' and 'my actions are controlled by an external force (passivity experience)' are the key symptoms suggesting F23.1. Whether these first-rank symptoms appear transiently in a polymorphic context or are persistent and fixed is important in differentiating from schizophrenia.
Physical examination and neurological findings: generally normal as in F23.0, and exclusion of organic causes is needed when neurological abnormalities are present.
Screening for F23.1 follows the same approach as F23.0, and immediate evaluation when acute psychotic symptoms appear is key. In F23.1, systematic confirmation of Schneider first-rank symptoms is especially important.
Structured interview to confirm first-rank symptoms: among the Positive and Negative Syndrome Scale (PANSS), the positive symptom subscale (P1-P7) and the items related to Schneider first-rank symptoms on the general psychopathology scale (G9: passivity/control experiences, G5: grandiose preoccupation, G3: guilt) are systematically evaluated. The presence and characteristics of first-rank symptoms are confirmed in the schizophrenia section of the SCID-5 (Structured Clinical Interview).
Exclusion of organic causes: the same tests to exclude organic causes as for F23.0 are needed. In particular, autoimmune encephalitis (anti-NMDAR antibody, anti-LGI1 antibody, anti-CASPR2 antibody, etc.) can cause first-rank symptoms such as passivity experiences along with acute-onset psychosis-like symptoms, so autoimmune antibody testing is recommended when clinically suspected.
Brain imaging: brain MRI is ideally performed in all patients with a first episode for the purpose of excluding organic causes. In particular, if MRI white matter abnormalities or anterior temporal lobe abnormalities are found in F23.1, they strongly suggest autoimmune encephalitis or another organic cause.
The diagnosis of F23.1 takes the form of the F23.0 criteria with the addition of accompanying schizophrenia-specific symptoms, and duration of less than 1 month is the key time criterion.
ICD-10 F23.1 diagnostic criteria: ① all criteria of F23.0 are met (acute onset within 2 weeks, polymorphic symptoms, course under 3 months, exclusion of organic causes); ② Schneider first-rank symptoms or schizophrenia-specific symptoms (note: part of criterion G1 of ICD-10 F20) are present; ③ symptoms do not last 1 month or longer (if persisting, reclassify as F20 or F25).
Diagnostic reclassification over time: patients diagnosed with F23.1 are reassessed weekly or every two weeks to track changes in symptoms and duration. If symptoms meeting the criteria for schizophrenia persist beyond 1 month, reclassify as F20 (schizophrenia). If a mood episode predominates, consider F25 (schizoaffective disorder) or F30 (psychosis with mood disorder).
Differential diagnosis: the main differential diagnoses are the first episode of schizophrenia (differentiated by whether it lasts 1 month or longer), F23.0 (no first-rank symptoms), schizoaffective disorder (mood episode predominant), organic psychosis (brain lesion, autoimmune encephalitis, etc.), substance-induced psychosis, and psychosis with mood disorder.
For treatment of F23.1, more active antipsychotic treatment and a longer maintenance treatment period than F23.0 are recommended. More careful long-term management considering the risk of transition to schizophrenia is needed.
Acute-phase antipsychotics: as in F23.0, atypical antipsychotics are the first choice. Because schizophrenia first-rank symptoms accompany, higher doses than in F23.0 (risperidone 2-4 mg/day, olanzapine 10-20 mg/day) may be needed. Response to acute-phase treatment is assessed weekly.
Maintenance treatment: unlike F23.0, in F23.1 maintenance treatment for 6-12 months or more is recommended even after complete remission. Because the risk of transition to schizophrenia is high, sufficient clinical evaluation and patient education must be carried out before drug discontinuation. Long-acting injectable (LAI) antipsychotics may be considered in patients with poor medication adherence.
Psychosocial treatment: after acute-phase recovery, family education, education on early warning signs of relapse, and training in stress management skills are included. Realistic and sufficient education about the possibility of transition to schizophrenia should be given to both the patient and family.
The prognosis of F23.1 is somewhat poorer than F23.0, and long-term follow-up is essential because of the possibility of transition to schizophrenia.
Short-term prognosis: the remission rate of the acute episode is high, similar to F23.0. Symptoms may resolve within several weeks to months, but the time to complete remission may be somewhat longer than in F23.0.
Long-term prognosis and transition: in long-term follow-up (5-10 years), about 20-30% transition to schizophrenia. About 30-40% experience recurrent episodes within the F23 group but do not develop chronic schizophrenia. The remaining 30-40% maintain complete remission without relapse over the long term. Overall functional prognosis is also somewhat poorer than in F23.0.
Factors affecting prognosis: family history of schizophrenia, duration of first-rank symptoms, decline in premorbid social functioning, male sex, and young age at onset are poor prognostic factors for transition to schizophrenia. An episode triggered by acute stress, female sex, and rapid symptom resolution are good prognostic factors.
Prevention of F23.1 requires, in addition to the stress management and relapse prevention principles of F23.0, a more intensive prevention strategy considering the risk of transition to schizophrenia.
Prevention of transition to schizophrenia: it is important to include F23.1 patients in early psychosis prevention and intervention programs. Clinical high-risk (CHR) state management techniques—low-dose antipsychotics, cognitive behavioral therapy (CBT), and omega-3 fatty acid supplementation—may help prevent transition to schizophrenia in F23.1 patients. Because use of cannabis and other psychostimulants markedly raises the risk of transition, education on prevention of substance use is essential.
Long-term follow-up system: regular psychiatric follow-up (at 3-6 month intervals) for at least 2-3 years after the F23.1 diagnosis is recommended. Education of patients and families about warning symptoms of relapse (decreased sleep, social withdrawal, increased bizarre thinking) enables early re-intervention. At relapse, immediate re-administration of antipsychotics and intensive treatment minimize transition to schizophrenia.
Pillmann F, Marneros A. Longitudinal follow-up in acute and transient psychotic disorders and schizophrenia. British Journal of Psychiatry. 2005;187:286-287. DOI: 10.1192/bjp.187.3.286. PMID: 16135868.
Pillmann F, Haring A, Balzuweit S, Marneros A. Bouffée délirante and ICD-10 acute and transient psychoses: a comparative study. Australian & New Zealand Journal of Psychiatry. 2003;37(3):327-333. DOI: 10.1046/j.1440-1614.2003.01175.x. PMID: 12780471.
Marneros A, Pillmann F, Haring A, Balzuweit S, Blöink R. Features of acute and transient psychotic disorders. European Archives of Psychiatry and Clinical Neuroscience. 2003;253(4):167-174. DOI: 10.1007/s00406-003-0420-y. PMID: 12920591.
Castagnini A, Berrios GE. Acute and transient psychotic disorders (ICD-10 F23): a review from a European perspective. European Archives of Psychiatry and Clinical Neuroscience. 2009;259(8):433-443. DOI: 10.1007/s00406-009-0008-3. PMID: 19247624.
Jorgensen P, Bennedsen B, Christensen J, Hyllested A. Acute and transient psychotic disorder: a 1-year follow-up study. Acta Psychiatrica Scandinavica. 1997;96(2):99-104. DOI: 10.1111/j.1600-0447.1997.tb09910.x. PMID: 9272193.
Singh SP, Burns T, Amin S, Jones PB, Harrison G. Acute and transient psychotic disorders: precursors, epidemiology, course and outcome. British Journal of Psychiatry. 2004;185:452-459. DOI: 10.1192/bjp.185.6.452. PMID: 15572741.
Susser E, Wanderling J. Epidemiology of nonaffective acute remitting psychosis vs schizophrenia. Archives of General Psychiatry. 1994;51(4):294-301. DOI: 10.1001/archpsyc.1994.03950040038004. PMID: 8161289.
Pillmann F, Haring A, Balzuweit S, Blöink R, Marneros A. The concordance of ICD-10 acute and transient psychoses and DSM-IV brief psychotic disorder. Psychological Medicine. 2002;32(3):525-533. DOI: 10.1017/S003329170200529X. PMID: 11989997.
Murray RM, Van Os J. Predictors of outcome in schizophrenia. Journal of Clinical Psychopharmacology. 1998;18(2 Suppl 1):2S-4S. PMID: 9541145.
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: WHO; 1992. (See the F23.1 classification criteria.)